The estimated Net Worth of Elizabeth Yeu Lin is at least $170 Mille dollars as of 24 June 2024. Elizabeth Lin owns over 3,350 units of Tarsus Pharmaceuticals stock worth over $170,130 and over the last 8 years Elizabeth sold TARS stock worth over $0.
Sign up
Elizabeth Lin TARS stock SEC Form 4 insiders trading
Elizabeth has made over 6 trades of the Tarsus Pharmaceuticals stock since 2022, according to the Form 4 filled with the SEC. Most recently Elizabeth exercised 3,350 units of TARS stock worth $106,530 on 24 June 2024.
The largest trade Elizabeth's ever made was buying 18,400 units of Tarsus Pharmaceuticals stock on 14 September 2022 worth over $296,608. On average, Elizabeth trades about 2,407 units every 49 days since 2017. As of 24 June 2024 Elizabeth still owns at least 5,350 units of Tarsus Pharmaceuticals stock.
You can see the complete history of Elizabeth Lin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Elizabeth Lin's mailing address?
Elizabeth's mailing address filed with the SEC is 25651, Atlantic Ocean Drive, Lake Forest, Orange County, California, 92630, United States.
Insiders trading at Tarsus Pharmaceuticals
Over the last 4 years, insiders at Tarsus Pharmaceuticals have traded over $38,362,333 worth of Tarsus Pharmaceuticals stock and bought 1,047,656 units worth $16,525,269 . The most active insiders traders include Investments, Lpwong Roderic..., Capital Ix, Llc Vivo Capita... e William J Phd Link. On average, Tarsus Pharmaceuticals executives and independent directors trade stock every 10 days with the average trade being worth of $729,047. The most recent stock trade was executed by William J Phd Link on 12 August 2024, trading 35,000 units of TARS stock currently worth $912,800.
What does Tarsus Pharmaceuticals do?
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
What does Tarsus Pharmaceuticals's logo look like?
Complete history of Elizabeth Lin stock trades at Staar Surgical Co e Tarsus Pharmaceuticals
Tarsus Pharmaceuticals executives and stock owners
Tarsus Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Dr. Bobak R. Azamian M.D.,
Co-Founder, Pres, CEO & Director -
Dr. Seshadri Neervannan Ph.D.,
Chief Operating Officer -
Leonard M. Greenstein,
Chief Financial Officer -
Kim Norman,
Sr. Director of Fin. -
Michael Holdbrook,
VP of Clinical Affairs -
Aziz Mottiwala,
Chief Commercial Officer -
Dianne C. Whitfield,
Chief HR Officer -
Matthew Rossen M.B.A.,
VP of Marketing -
Dr. Bryan Wahl J.D., M.D.,
Gen. Counsel -
David Nakasone,
Head of Investor Relations -
Jeffrey S Farrow,
See Remarks -
Scott W Morrison,
Director -
Michael Ackermann,
Director -
Jason E. Tester,
Director -
Capital Ix, Llc Vivo Capita...,
-
Life Sciences Ix, L.P.Fhmls...,
-
Limited Partnership Viii Ho...,
10% owner -
Jose M. Trevejo,
CHIEF MEDICAL OFFICER -
Bryan Wahl,
General Counsel -
Dianne C. Whitfield,
Chief Human Resources Officer -
Leonard M. Greenstein,
Chief Financial Officer -
Wendy L Yarno,
Director -
Aziz Mottiwala,
Chief Commercial Officer -
Mark J. Holdbrook,
V.P., Clinical Affairs -
Investments, Lpwong Roderic...,
-
Bhaskar Chaudhuri,
Director -
Andrew D. Goldberg,
Director -
Rosemary A Crane,
Director -
Elizabeth Yeu Lin,
Director -
Bobak R. Azamian,
President/CEO and Board Chair -
William J Phd Link,